These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 8387973)
1. Lipase inhibition: a novel concept in the treatment of obesity. Drent ML; van der Veen EA Int J Obes Relat Metab Disord; 1993 Apr; 17(4):241-4. PubMed ID: 8387973 [TBL] [Abstract][Full Text] [Related]
2. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Muls E; Kolanowski J; Scheen A; Van Gaal L; Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595 [TBL] [Abstract][Full Text] [Related]
3. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Drent ML; Larsson I; William-Olsson T; Quaade F; Czubayko F; von Bergmann K; Strobel W; Sjöström L; van der Veen EA Int J Obes Relat Metab Disord; 1995 Apr; 19(4):221-6. PubMed ID: 7627244 [TBL] [Abstract][Full Text] [Related]
4. A one-year trial to assess the value of orlistat in the management of obesity. James WP; Avenell A; Broom J; Whitehead J Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173 [TBL] [Abstract][Full Text] [Related]
5. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380 [TBL] [Abstract][Full Text] [Related]
6. Influences of fat restriction and lipase inhibition on gastric emptying in obesity. Mathus-Vliegen EM; van Ierland-van Leeuwen ML; Bennink RJ Int J Obes (Lond); 2006 Aug; 30(8):1203-10. PubMed ID: 16462818 [TBL] [Abstract][Full Text] [Related]
7. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013 [TBL] [Abstract][Full Text] [Related]
8. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Finer N; James WP; Kopelman PG; Lean ME; Williams G Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623 [TBL] [Abstract][Full Text] [Related]
9. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients]. Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M; Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429 [TBL] [Abstract][Full Text] [Related]
10. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204 [TBL] [Abstract][Full Text] [Related]
11. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632 [TBL] [Abstract][Full Text] [Related]
12. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478 [TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983 [TBL] [Abstract][Full Text] [Related]
14. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. Svendsen M; Helgeland M; Tonstad S J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027 [TBL] [Abstract][Full Text] [Related]
15. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259 [TBL] [Abstract][Full Text] [Related]
16. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261 [TBL] [Abstract][Full Text] [Related]
17. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727 [TBL] [Abstract][Full Text] [Related]